HIV感染女性启动整合酶链转移抑制剂后肝脂肪变性和纤维化的无创标志物
研究利用2007-2020年女性跨机构HIV研究数据,比较病毒学抑制的HIV感染女性换用或加用整合酶链转移抑制剂(INSTI)与继续非INSTI方案者5年内FIB4、APRI和NFS的变化,并在有瞬时弹性成像者中比较CAP、LS和FAST评分。结果显示,非肥胖女性中INSTI组NFS随时间增加更明显,且INSTI组CAP、LS、FAST评分更高,启动INSTI后1年内肝脂肪变风险增加。
要点
- 非肥胖HIV感染女性中,INSTI组较非INSTI组NFS随时间增加更明显(交互P=0.015)。
- INSTI组较非INSTI组CAP、LS和FAST评分更高,启动INSTI后1年内肝脂肪变风险增加。
- 肝脂肪变风险增加仅见于启动INSTI后第一年内。
核心结论
- HIV感染女性中,肝脂肪变风险仅在启动INSTI后第一年内增加。
- 作者认为需要纵向肝脏评估以明确这些变化是否与临床显著肝病相关。
研究设计与样本
- 利用2007-2020年女性跨机构HIV研究数据,比较病毒学抑制的HIV感染女性换用或加用INSTI与继续非INSTI抗逆转录病毒治疗者5年内FIB4、APRI和NFS的变化。
- 共纳入872名HIV感染女性(INSTI组323名,非INSTI组549名),其中280名(INSTI组146名,非INSTI组134名)有瞬时弹性成像测量。
主要发现
- 61%为非西班牙裔黑人,平均年龄47岁,平均体重指数31.4 kg/m2。
- 非肥胖女性中,INSTI组较非INSTI组NFS随时间增加更明显(研究组×时间,P=0.015),但FIB4或APRI无此差异。
- INSTI组较非INSTI组CAP更高(+25;95%CI:0.28-49;P=0.048)、LS更高(+1.23;1.01-1.49;P=0.038)、FAST评分更高(+1.97;1.17-3.31;P=0.011)。
- INSTI组较非INSTI组在启动INSTI后1年内发生肝脂肪变(CAP≥248 dB/m)的比值比为3.7(95%CI:1.2-11.4;P=0.021)。
局限性
- 作者认为需要纵向肝脏评估以明确这些变化是否与临床显著肝病相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The impact of integrase strand-transfer inhibitors (INSTIs) on steatotic liver disease in women with HIV (WWH) is unknown. METHODS: Using data collected in the Women's Interagency HIV Study from 2007-2020, change in Fibrosis-4 index (FIB4), aspartate aminotransferase to platelet ratio index (APRI), and nonalcoholic fatty liver disease fibrosis score (NFS) over 5 years was compared between virologically suppressed WWH who switched to or added an INSTI to their antiretroviral therapy (ART) and WWH remaining on non-INSTI ART. In participants with transient elastography (TE) measures, estimates of hepatic steatosis (controlled attenuation parameter [CAP]), fibrosis (liver stiffness [LS]), and steatohepatitis (FibroScan-aspartate aminotransferase [FAST] scores) were compared by group. RESULTS: A total of 872 WWH (323 INSTI, 549 non-INSTI) were included, and 280 (146 INSTI, 134 non-INSTI) had TE. Of these, 61% were non-Hispanic Black; mean age was 47 years and body mass index was 31.4 kg/m2. Among non-obese women, those in the INSTI versus non-INSTI group had a greater increase in NFS (but not FIB4 or APRI) over time (study group × time, P = .015). Those in the INSTI versus non-INSTI group also had greater CAP (+25; 95% CI: .28-49; P = .048), LS (+1.23; 1.01-1.49; P = .038), and FAST scores (+1.97; 1.17-3.31; P = .011) and a 3.7 (1.2-11.4; P = .021) greater odds of having hepatic steatosis (CAP ≥248 dB/m) within 1 year of starting an INSTI. CONCLUSIONS: Hepatic steatosis risk was increased only within the first year following INSTI initiation among WWH. Longitudinal hepatic assessments are warranted to evaluate whether these changes are associated with clinically significant liver disease.
引用
- Yu MA, Gerig L, Mehta CC, et al. Noninvasive Markers of Hepatic Steatosis and Fibrosis Following Integrase Strand-Transfer Inhibitor Initiation in Women With HIV. Clin Infect Dis. 2025. PMID: 39899358. doi:10.1093/cid/ciaf049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。